CAR-T cell and bispecific antibody (BsAb) therapies are revolutionizing cancer treatment, yet access remains limited to Academic Medical Centers (AMCs) and affiliated outpatient clinics. Expanding these transformative therapies to community oncology practices could unlock new possibilities for patient care—if the barriers can be addressed.
In our Special Topics Report, we dive deep into the key questions shaping the future of CAR-T and BsAb adoption:
- Can CAR-Ts and BsAbs be effectively integrated into community oncology?
- What are the major barriers to adoption?
- How can these therapies fit best in the broader oncology care continuum?
Whether you're navigating commercialization strategies, seeking partnership opportunities, or aiming to improve market access, this report delivers actionable insights to guide your decisions.
Key Benefits:
- Understand the logistical, financial, and clinical challenges impacting broader adoption.
- Identify untapped opportunities for bringing CAR-T and BsAb therapies into the community setting.
- Gain a strategic edge with data-driven analysis to shape your market access plans.
Want to get started?
Contact Ramon Auciello to learn more about this report and gain access to these key insights.